AVXL
Anavex Life Sciences Corp
2.40$
+0.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -4.1% | -2.2% | -2.2% | -4.2% | -8.5% | -5.6% | -12.6% | +1.4% | +28.1% | -3.2% | -6.7% | |
| – | -4.1% | -2.4% | -2.1% | -4.2% | -8.5% | -5.6% | -13.6% | +2.6% | +28.1% | -3.2% | -6.7% | |
| – | -4.8% | -3.0% | -0.5% | -4.7% | -8.6% | -4.1% | -12.6% | +1.4% | +28.4% | -3.3% | -7.1% | |
| – | -4.8% | -3.0% | -0.5% | -4.7% | -8.6% | -4.1% | -12.6% | +1.4% | +28.4% | -3.3% | -7.1% | |
| – | +31.0% | +6.6% | -54.6% | +42.4% | +4.4% | -74.0% | +23.1% | -1.3% | +4.3% | +10.4% | +6.8% | |
| – | -0.3% | -23.5% | +23.0% | +30.2% | -14.2% | +32.4% | -34.0% | -22.0% | -28.8% | +10.8% | +9.0% | |
| – | -0.3% | -23.5% | +23.0% | +30.2% | -14.2% | +32.4% | -34.0% | -22.0% | -28.8% | +10.8% | +9.0% | |
| – | – | – | -200.0% | – | – | – | – | – | – | – | – | |
| – | -0.7% | -13.2% | -6.0% | +174.8% | -52.6% | +53.2% | -3.7% | -37.0% | -37.9% | -4.5% | +45.1% | |
| – | -4.4% | -0.3% | -4.0% | -7.3% | -7.8% | -10.1% | -8.8% | +4.3% | +33.5% | -3.9% | -7.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.9% | +0.5% | +2.5% | -0.6% | +1.0% | +0.3% | +0.4% | +0.6% | +3.7% | +4.1% | -1.3% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.